Drug Trial Radar · NCT07844148
A Study to Compare GNR-139 and Eylea® in Patients With nAMD
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Participants will be randomly assigned to receive either GNR-139 or Eylea. Neither the participants nor the study doctors will know which treatment is being administered. Both drugs will be given as an intravitreal injection dose of 8 mg (0.07 mL at a concentration of 114.3 mg/mL). Patients meeting the eligibility criteria will be randomised in a 2:1 ratio into one of two treatment groups: * Group I (GNR-139): 120 patients; * Group II (Eylea®): 60 patients. The main goal of the study is to evaluate if GNR-139 has similar efficacy to Eylea. This will be determined by measuring the change in the Best-Corrected Visual Acuity (BCVA) score at Week 8 in participants who completed the treatment.
Conditions
- nAMD
Interventions
afliberceptBiological
GNR-139 is being developed as a biosimilar to the reference medicinal product Eylea®
EyleaBiological
Eylea® (INN: aflibercept), 114.3 mg/mL, solution for intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in BCVA, assessed by the number of letters read correctly on the ETDRS chart, at Week 8.Time frame: Week 8
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Cheboksary branch of S. Fyodorov Eye Microsurgery Federal State Institution
Cheboksary, Cheboksary, Russia · Not yet recruiting
Medical organization "Optic-Center" Ltd
Chelyabinsk, Chelyabinsk Oblast, Russia · Not yet recruiting
Sverdlovsk Regional Clinical Hospital No.1
Yekaterinburg, Ekaterinburg, Russia · Not yet recruiting
Ivanovo regional clinical hospital
Ivanovo, Ivanovo Oblast, Russia · Recruiting
Federal State Budgetary Institution "Helmholtz National Medical Research Center of Eye Diseases" of the Ministry of Health of the Russian Federation
Moscow, Moscow, Russia · Not yet recruiting
Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine"
Moscow, Moscow, Russia · Not yet recruiting
S.Fyodorov Eye Microsurgery Federal State Institution
Moscow, Moscow, Russia · Not yet recruiting
Volga District Medical Center of the Federal Medical and Biological Agency
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia · Recruiting
Novosibirsk Regional Clinical Hospital
Novosibirsk, Novosibirsk Oblast, Russia · Not yet recruiting
V.P. Vykhodtsev Clinical Ophthalmology Hospital
Omsk, Omsk Oblast, Russia · Not yet recruiting
S.M. Kirov Military Medical Academy
Saint Petersburg, Saint Peterburg, Russia · Not yet recruiting
X7 Clinical Research Co
Saint Petersburg, Saint Peterburg, Russia · Not yet recruiting
LLC "Eye Diseases Clinic"
Kazan', Tatarstan Republic, Russia · Not yet recruiting
LLC Eyes Clinic-Opticstyle
Vladimir, Vladimirskaya Oblast’, Russia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.